Cambridge Investment Research Advisors’s Nutraceutical International Co NUTR Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2017
Q2
Sell
-10,988
Closed -$342K 2005
2017
Q1
$342K Hold
10,988
0.01% 1290
2016
Q4
$384K Sell
10,988
-4,000
-27% -$127K 0.01% 1139
2016
Q3
$468K Sell
14,988
-4,000
-21% -$103K 0.01% 1073
2016
Q2
$440K Hold
18,988
0.01% 989
2016
Q1
$462K Hold
18,988
0.01% 940
2015
Q4
$490K Sell
18,988
-6,000
-24% -$147K 0.01% 858
2015
Q3
$590K Sell
24,988
-5,000
-17% -$120K 0.02% 684
2015
Q2
$742K Sell
29,988
-2,000
-6% -$42.2K 0.02% 629
2015
Q1
$630K Hold
31,988
0.02% 685
2014
Q4
$690K Hold
31,988
0.02% 624
2014
Q3
$669K Hold
31,988
0.02% 670
2014
Q2
$763K Sell
31,988
-4,540
-12% -$111K 0.03% 552
2014
Q1
$949K Sell
36,528
-23,460
-39% -$609K 0.04% 438
2013
Q4
$1.61M Buy
+59,988
New +$1.49M 0.07% 292

Other funds holding NUTR

Cambridge Investment Research Advisors's NUTR Position: Q2 2017 in Review

Cambridge Investment Research Advisors sold out of Nutraceutical International Co (NUTR) in Q2 2017, closing a stake of 10,988 shares — an estimated $342K sold.

Cambridge Investment Research Advisors first reported a position in NUTR in Q4 2013 and held it in 14 quarters. The position peaked at $1.61M in Q4 2013. 86 funds tracked by Wall St. Rank hold NUTR as of Q2 2017.

  • Cambridge Investment Research Advisors reported no remaining Nutraceutical International Co position as of Q2 2017 after selling out during the quarter.
  • Cambridge Investment Research Advisors sold 10,988 Nutraceutical International Co shares in Q2 2017, an estimated $342K.
  • Cambridge Investment Research Advisors first reported a position in Nutraceutical International Co in Q4 2013 and held it in 14 quarters.
  • Cambridge Investment Research Advisors's Nutraceutical International Co position peaked at $1.61M in Q4 2013.
  • 86 funds tracked by Wall St. Rank held Nutraceutical International Co as of Q2 2017.

Based on Cambridge Investment Research Advisors's 13F filing for Q2 2017, filed 8 Aug 2017.